Literature DB >> 21622650

Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities.

Aurore Perrot1, Isabelle Luquet, Arnaud Pigneux, Francine Mugneret, Jacques Delaunay, Jean-Luc Harousseau, Carole Barin, Jean-Yves Cahn, Philippe Guardiola, Chantal Himberlin, Christian Recher, Norbert Vey, Bruno Lioure, Mario Ojeda-Uribe, Nathalie Fegueux, Christian Berthou, Edouard Randriamalala, Marie C Béné, Norbert Ifrah, Francis Witz.   

Abstract

The prognosis of acute myeloid leukemia (AML) is very poor in elderly patients, especially in those classically defined as having unfavorable cytogenetics. The recent monosomal karyotype (MK) entity, defined as 2 or more autosomal monosomies or combination of 1 monosomy with structural abnormalities, has been reported to be associated with a worse outcome than the traditional complex karyotype (CK). In this retrospective study of 186 AML patients older than 60 years, the prognostic influence of MK was used to further stratify elderly patients with unfavorable cytogenetics. CK was observed in 129 patients (69%), and 110 exhibited abnormalities according to the definition of MK (59%). MK(+) patients had a complete response rate significantly lower than MK(-) patients: 37% vs 64% (P = .0008), and their 2-year overall survival was also decreased at 7% vs 22% (P < .0001). In multivariate analysis, MK appeared as the major independent prognostic factor related to complete remission achievement (odds ratio = 2.3; 95% confidence interval, 1-5.4, P = .05) and survival (hazard ratio = 1.7; 95% confidence interval, 1.1-2.5, P = .008). In the subgroup of 129 CK(+) patients, survival was dramatically decreased for MK(+) patients (8% vs 28% at P = .03). These results demonstrate that MK is a major independent factor of very poor prognosis in elderly AML.

Entities:  

Mesh:

Year:  2011        PMID: 21622650     DOI: 10.1182/blood-2010-09-307264

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

Review 1.  Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia.

Authors:  Yahya Daneshbod; Leila Kohan; Vahideh Taghadosi; Olga K Weinberg; Daniel A Arber
Journal:  Curr Treat Options Oncol       Date:  2019-02-11

Review 2.  Management of primary refractory acute myeloid leukemia in the era of targeted therapies.

Authors:  Christine M McMahon; Alexander E Perl
Journal:  Leuk Lymphoma       Date:  2018-09-20

3.  Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT.

Authors:  M A Kharfan-Dabaja; M Labopin; A Bazarbachi; R M Hamladji; D Blaise; G Socié; B Lioure; A Bermudez; L Lopez-Corral; R Or; W Arcese; N Fegueux; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-06-30       Impact factor: 5.483

4.  Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission.

Authors:  Masamitsu Yanada; Saiko Kurosawa; Takuhiro Yamaguchi; Takuya Yamashita; Yukiyoshi Moriuchi; Hiroatsu Ago; Jin Takeuchi; Hirohisa Nakamae; Jun Taguchi; Toru Sakura; Yasushi Takamatsu; Fusako Waki; Hiroki Yokoyama; Masato Watanabe; Nobuhiko Emi; Takahiro Fukuda
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

5.  Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials.

Authors:  Stephen A Strickland; Zhuoxin Sun; Rhett P Ketterling; Athena M Cherry; Larry D Cripe; Gordon Dewald; Hugo F Fernandez; Gary A Hicks; Rodney R Higgins; Hillard M Lazarus; Mark R Litzow; Selina M Luger; Elisabeth M Paietta; Jacob M Rowe; Gail H Vance; Peter Wiernik; Anne E Wiktor; Yanming Zhang; Martin S Tallman
Journal:  Leuk Res       Date:  2017-05-12       Impact factor: 3.156

Review 6.  Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia.

Authors:  T Bochtler; S Fröhling; A Krämer
Journal:  Leukemia       Date:  2015-02-12       Impact factor: 11.528

7.  Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus.

Authors:  Joseph M Brandwein; Michelle Geddes; Jeannine Kassis; Andrea K Kew; Brian Leber; Thomas Nevill; Mitchell Sabloff; Irwindeep Sandhu; Andre C Schuh; John M Storring; John Ashkenas
Journal:  Am J Blood Res       Date:  2013-05-05

8.  Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies.

Authors:  Marcelo C Pasquini; Mei-Jie Zhang; Bruno C Medeiros; Philippe Armand; Zhen-Huan Hu; Taiga Nishihori; Mahmoud D Aljurf; Görgün Akpek; Jean-Yves Cahn; Mitchell S Cairo; Jan Cerny; Edward A Copelan; Abhinav Deol; César O Freytes; Robert Peter Gale; Siddhartha Ganguly; Biju George; Vikas Gupta; Gregory A Hale; Rammurti T Kamble; Thomas R Klumpp; Hillard M Lazarus; Selina M Luger; Jane L Liesveld; Mark R Litzow; David I Marks; Rodrigo Martino; Maxim Norkin; Richard F Olsson; Betul Oran; Attaphol Pawarode; Michael A Pulsipher; Muthalagu Ramanathan; Ran Reshef; Ayman A Saad; Wael Saber; Bipin N Savani; Harry C Schouten; Olle Ringdén; Martin S Tallman; Geoffrey L Uy; William A Wood; Baldeep Wirk; Waleska S Pérez; Minoo Batiwalla; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-29       Impact factor: 5.742

Review 9.  Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia.

Authors:  Mohamed L Sorror; Frederick R Appelbaum
Journal:  Expert Rev Hematol       Date:  2013-10-02       Impact factor: 2.929

10.  Acute myeloid leukemia with adverse cytogenetic risk.

Authors:  Krzysztof Mrózek; Clara D Bloomfield
Journal:  Oncology (Williston Park)       Date:  2012-08       Impact factor: 2.990

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.